Proprietary antioxidant complex shown to safeguard DNA from radiation exposure during aortic procedures

Kieran Murphy

Cora Therapeutics has announced the presentation of the results of a clinical trial at the Canadian Association of Interventional Radiologists (CAIR) annual meeting  (25–27 May, Quebec City, Canada), assessing the efficacy of its proprietary antioxidant complex in safeguarding DNA from radiation exposure during aortic aneurysm stenting procedures guided by X-ray technology.

Kieran Murphy, founder, inventor, and chief medical officer of Cora Therapeutics, presented the results at the CAIR meeting.

During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure. The results clearly showed the treated group experiencing a significant 78% reduction in DNA breaks detected by P53 tests in their cell nucleus, surpassing expectations compared to the placebo group.

Murphy’s team has demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature. The group given the antioxidant formulation exhibited a 54% decrease in mitochondrial DNA damage based on STAT 3 testing when compared to the placebo group. Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

The was conducted by two independent teams of scientists, one at Princess Margaret Hospital, University Health Network, Toronto, and the other at McMaster University, Hamilton, Ontario, Canada.

The research findings will now undergo the peer-reviewed publication process. This antioxidant formulation has the potential to mitigate DNA breaks in patients undergoing computed tomography (CT) scans, X-rays, mammography, angiography, dental X-rays, and could become an integral part of the daily routine for the 2 million healthcare workers worldwide who perform cardiac and angiographic interventions under X-ray guidance or work in radiology and cardiology departments.

Murphy’s previous prospective, randomised human study showcased an impressive over 90% reduction in DNA breaks among patients undergoing Nuclear Medicine bone scans. This research was published in the Journal of Vascular Interventional Radiology in 2016.

Radiation, classified as an oxidative stressor, leads to the accumulation of harmful free radicals in the body, much like air pollution, ultraviolet (UV) light, smoking, processed diets, and frequent flying. Unprotected, these deleterious free radicals infiltrate DNA, elevating the risk of DNA damage and gene mutation. However, the Halo antioxidant complex, which can be taken daily or one hour before radiation exposure, has demonstrated significant efficacy in reducing DNA breaks, as indicated by the collected data.

Halo is an antioxidant formulation that consists of carefully selected natural ingredients that comply with NHPD guidelines, ensuring maximum safety and optimal efficacy while upholding the highest standards for nutraceutical products. The patented blend of ingredients effectively neutralises free radicals, preventing them from damaging the body’s cells. Cora Therapeutics has employed pharmaceutical-level scientific rigor to develop this innovative nutraceutical.

Halo has received clearance from Health Canada and the US Food and Drug Administration (FDA). It is protected by four issued patents globally and has been the subject of nine peer-reviewed publications, solidifying its scientific validity and potential.


Please enter your comment!
Please enter your name here